Results: Median ADAMTS13 activity was significantly reduced in the early phase (71.96% vs.
95.5%, P < 0.01) but not in the late phase after TIA or stroke compared with controls (86.3% vs.
95.5%, P = 0.19). There was a significant inverse relationship between ADAMTS13 activity and VWF:Ag levels in the early phase (r = -0.31; P = 0.024), but not in the late phase after TIA or stroke (P = 0.74). There was a positive correlation between ADAMTS13 activity and C-ADP closure times in early phase patients only, likely mediated via VWF:Ag levels.
Discussion: ADAMTS13 activity is reduced and VWF:Ag expression is increased within 4 weeks of TIA or ischaemic stroke onset, and can promote enhanced platelet adhesion and aggregation in response to stimulation with collagen and ADP via VWF-mediated pathways.
These data improve our understanding of the dynamic haemostatic and thrombotic profiles of ischaemic cerebrovascular disease (CVD) patients, and are important in view of the potential future role that ADAMTS13 may have to play as an anti-thrombotic agent in CVD. (4) and is associated with accumulation of prothrombotic ultra-large von Willebrand factor (ULVWF) multimers. Murine stroke models have suggested that reduced ADAMTS13 activity significantly aggravates ischaemic brain injury. (5, 6) A number of studies have identified either low ADAMTS13 antigen levels or activity in coronary artery disease (7) (8) (9) or at a single timepoint after ischaemic stroke, (10) (11) (12) but other studies have not confirmed these findings.(1) Increased VWF levels have been reported in ischaemic cerebrovascular disease (CVD) patients,(1, [13] [14] [15] and may cause platelet hyperreactivity and shortened 'closure times' on a high shear stress-dependent platelet function analyser called the PFA-100 ® . (16) (17) (18) ADAMTS13 activity has been shown to be inversely correlated with VWF antigen levels, (19) but to our knowledge, the impact of ADAMTS13 activity on platelet function on the PFA-100 ® in patients in both the early and late phases after TIA and stroke has not been studied.
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The aims of this study were to assess ADAMTS13 activity in both the early and late phases after 'non-TTP related' TIA or ischaemic stroke, to assess the relationship between ADAMTS13 activity and VWF antigen (VWF:Ag) levels in CVD patients, and to determine whether ADAMTS13 activity independently influences platelet reactivity in CVD. We hypothesised that ADAMTS13 activity would be reduced in CVD patients versus controls, and that ADAMTS13 activity would correlate with VWF:Ag levels and platelet reactivity in ischaemic CVD.
Methods
CVD Patient Inclusion Criteria
Consecutive eligible patients referred by General Practitioners or Consultant colleagues to our secondary and tertiary referral stroke prevention outpatient clinic or inpatient stroke neurology or liaison neurology service at the National Hospital for Neurology and Neurosurgery, University
College London Hospitals, UK were recruited to this prospective pilot observational analytical case-control study. Patients were included if they were older than 18 years of age, had experienced a TIA or ischaemic stroke within the preceding 4 weeks (early phase), had been commenced on aspirin, and were likely to be available for clinical and laboratory follow-up at least 3 months after symptom onset (late phase).The study was approved by the Local Research Ethics Committees of the participating Hospitals. Written informed consent (or written assent, where appropriate) was obtained in all cases.
A C C E P T E D M A N U S C R I P T or when other investigations were uninformative, as previously described. (18) The underlying mechanism responsible for the TIA or ischaemic stroke was categorised according to slight modifications of the TOAST classification as large artery atherosclerotic, lacunar, cardio-
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embolic, other determined, and undetermined aetiology ( Table 2) . (20) For the purpose of this study, large artery atherosclerotic TIA or stroke specifically referred to TIA or stroke in the vascular territory supplied by a severe (>70%) ipsilateral extracranial carotid stenosis or occlusion to comply with inclusion criteria for other ongoing collaborative studies in our laboratory. The late phase follow-up in the large artery atherosclerotic subgroup was performed ≥3 months after carotid surgery or endovascular treatment, unless this treatment had been delayed for at least 3 months after the initial event.
Control Subjects Inclusion and Exclusion Criteria
Control subjects were recruited from the staff at The Haemostasis Research Unit, University
College London Hospitals, from the local population, and from amongst spouses of patients and control subjects. Subjects were excluded from the control group if they had a history of known vascular disease, or evidence of asymptomatic severe (> 70%) carotid or vertebral artery stenosis on colour Doppler ultrasound imaging. Otherwise, the exclusion criteria were identical to those applied to the patient group. It was expected that control subjects would have a different vascular risk profile to the patient population.
Blood Sampling and Laboratory Tests
All subjects were rested for at least 20 minutes before venepuncture, and free-flowing blood was collected using a 21-G Butterfly needle (Venisystems™, Abbott, Ireland) and a Vacutainer Epinephrine (C-EPI) between 2 and 2.5 hours after venepuncture, as previously described. (18) The maximum closure time recorded by the device is 300s, and we arbitrarily defined closure times >300s as 301s. (18) The next two citrated samples were used to prepare double-centrifuged ( Stepwise regression assessed the impact of ADAMTS13 activity on PFA-100 ® closure times whilst controlling for VWF:Ag levels. P < 0.05 was considered statistically significant. All statistical calculations were performed with Minitab 6.0 for Windows. CVD patients were older (P<0.001), and as expected, vascular risk factors were more common in CVD patients than controls (table 1) . In particular, hypertension and a definite diagnosis of hyperlipidaemia were more common in early and late phase CVD patients, and the proportion of smokers was higher in late phase patients than controls. No study subject had a platelet count < 150 x 10 9 /L, and none had any other clinical features of TTP. Median ADAMTS13 activity was significantly reduced in the early phase after TIA or stroke compared with controls (71.96% vs. 95.5%, P< 0.01; figure 1). After controlling for differences in hypertension, hyperlipidemia, smoking status, and statin use between groups, significant differences in ADAMTS13 activity between early phase CVD patients and controls persisted (P < 0.02).There was no significant difference in ADAMTS13 activity between late phase CVD patients and controls (86.03% vs. 95.5%, P = 0.19;figure 1), even after controlling 12 for the above factors (P = 0.561). Post-hoc analysis indicated that there was no significant difference in ADAMTS13 activity between TIA (N = 3) and ischaemic stroke patients (N = 50; P = 0.658), but the number of subjects in the TIA subgroup was far too small to make any definitive conclusions, and this study was not designed to address such a subgroup analysis.
Results
Between
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Figure 1:
Comparison of median ADAMTS13 levels between controls and early and late phase CVD patients. P values refer to comparisons between patients and controls.
There was no significant correlation between ADAMTS13 activity and age in our patient population in the early phase (r = -0.22, P = 0.12), nor was there any significant difference in ADAMTS13 activity between different stroke subtypes (Tukey ANOVA, P = 0.50).
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As reported previously,(18) VWF:Ag levels were higher in the early (201.83 IU/dl, P < 0.001; figure 2 ) and late phases after TIA or stroke (175.38 IU/dl;P < 0.001) than in controls (123.87 IU/dl; figure 2).
Figure 2:
Comparison of mean VWF antigen levels (IU/dl) between controls and early and late phase CVD patients. P values refer to comparisons between controls and patients.
In our CVD population, there was a distinct inverse relationship between ADAMTS13 activity and VWF:Ag levels in the early phase (r = -0.31, P = 0.024; figure 3 ) but not in the late phase after symptom onset (r = -0.2, P = 0.738).
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14 There was a positive correlation between ADAMTS13 activity and C-ADP closure times (r = 0.35, P= 0.012) but not C-EPI closure times (r = 0.24; P = 0.092) on the PFA-100 ® in the early CVD group, suggesting that reduced ADAMTS13 activity might be associated with shorter C-ADP closure times, and hence platelet hyper-reactivity to collagen-ADP early after TIA or stroke. However, when stepwise logistic regression analysis was performed to control for the influence of VWF:Ag levels on the potential relationship between ADAMTS13 activity and C-ADP closure times, the relationship became non significant (P = 0.066).
Of the 53 early phase patients, 23 had reduced ADAMTS13 activity < 66% of PNP in our laboratory, but none of these patients had reduced ADAMTS13 antigen levels in the early or late
15 phase after symptom onset. Three of these 23 patients had elevated anti-ADAMTS13 IgG autoantibody titres (defined as > 9.6 AU/dl) in the early phase, but only one of these patients had persistent anti-ADAMTS13 IgG auto-antibodies in the late phase.
Discussion
This novel pilot study has shown that ADAMTS13 activity is significantly reduced in the early but not in the late phase after TIA or ischaemic stroke. Our early phase samples were collected sooner after symptom onset than in prior published studies in CVD patients (mean time to blood sampling was just over 1 week; ( range: 0-27 days ), (1,10-12) and these novel data provide unique, important insights into the dynamic profile of ADAMTS13 and its relationship with VWF:Ag early after TIA or ischaemic stroke. One must accept that the lack of significant differences between late phase patients and controls could represent a type II error due to the smaller number of subjects studied ≥ 3 months after symptom onset. However, the lack of significantly reduced ADAMTS13 activity in late phase CVD patients suggests that this is a dynamic protease whose activity may decrease as an 'acute phase response' to TIA or ischaemic stroke, but returns to levels similar to those seen in controls during late-phase follow up.
Prior studies by our group (18) Our pilot hospital-based study is in agreement with these population-based data (19) because we also found that there was an inverse relationship between ADAMTS13 activity and VWF:Ag levels in early phase CVD patients. However, one cannot comment on the relationship between ADAMTS13 activity and levels of 'individual fractions' of circulating VWF multimers following TIA or stroke because our VWF assay measured overall VWF:Ag levels and did not differentiate between smaller, larger and ultra-large VWF multimers.
As stated above, previous studies have investigated whether low ADAMTS13 activity could be a risk factor for CVD or ischaemic heart disease. (7) (8) (9) (10) (11) (12) Desmopressin infusion induces the secretion of very large VWF multimers into the plasma,(25) producing plasma ULVWF levels similar to those seen with acute tissue hypoxia in vivo. (15) In vivo testing of healthy volunteers revealed a steep decline in ADAMTS13 activity after desmopressin infusion suggesting that the protease is consumed as it cleaves very large VWF multimers. (25) These desmopressin-induced effects also occur in systemic inflammation (26) which has been noted in ischaemic stroke. (27) Our study revealed initial low ADAMTS13 activity and a distinct inverse relationship between VWF:Ag levels and ADAMTS13 activity only in the early phase after TIA or ischaemic stroke.
Based on our longitudinal data, the early phase findings are consistent with the hypothesis that ADAMTS13 may be consumed or inactivated as it degrades ultra-large VWF multimers (25) associated with acute cerebral or ocular ischaemia rather than reflecting a 'pre-existing deficiency' of ADAMTS13 antigen in our CVD population.
Because the protease targets the largest, most thrombogenic multimers of VWF which have the greatest influence on platelet adhesion and aggregation,(28) lower ADAMTS13 activity, which would be expected to be associated with increased VWF:Ag levels, was associated with
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
17
'apparent platelet hyper-reactivity' and shorter C-ADP closure times. Stepwise logistic regression analysis revealed that it is highly likely that the relationship between ADAMTS13 activity and PFA-100 C-ADP closure times is mediated via VWF:Ag, and that ADAMTS13 itself does not directly influence closure times. By the late phase, ADAMTS13 activity was not lower than in controls, and the clear inverse relationship between ADAMTS13 and VWF:Ag levels seen in the early phase was no longer evident. This lack of a significant relationship between these two variables may also reflect a type II error due to the smaller number of subjects with late phase data, but could represent a shift towards normal VWF multimers in plasma over time, for which ADAMTS13 has less affinity, thus resulting in normalisation of ADAMTS13 activity during late phase follow up.
The exploratory laboratory assays that were performed in the patient subgroups with low ADAMTS13 activity indicate that the findings in our early phase CVD patients cannot not explained by a primary deficiency of ADAMTS13 antigen. Because only 3 of the 23 early phase CVD patients, and only one late phase CVD patient with low ADAMTS13 activity had positive anti-ADAMTS13 IgG auto-antibodies, one can conclude that the initial reduction in ADAMTS13 activity in non-TTP-related TIA or stroke is more likely to be due to an acute phase response, and cannot predominantly be attributed to the presence of the measured autoantibodies to ADAMTS13. (29) This study had some limitations. The study was designed to focus on CVD patients on aspirin monotherapy who also had simultaneous PFA-100 ® testing, so one cannot comment on the potential impact of other commonly-prescribed antiplatelet regimens, such as aspirin and dipyridamole or clopidogrel monotherapy on ADAMTS13 activity in TIA and ischaemic stroke.
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This issue deserves future study. Patient data were compared with controls who were not on Aspirin; however, there is no evidence from longitudinal studies that Aspirin therapy influences either circulating VWF antigen levels (30) or ADAMTS13 activity.(31) One of the more important conclusions to draw from this pilot study is that early phase CVD patients had lower levels of ADAMTS13 activity despite treatment with aspirin therapy at standard therapeutic doses used for secondary prevention of recurrent vascular events. Aspirin has been clearly shown to prolong C-EPI closure times in patients following TIA or stroke, (18, 32) and may well have influenced the analysis of the relationship between ADAMTS13 activity and C-EPI closure times. However, because we have demonstrated that it is highly likely that any apparent relationship between ADAMTS13 activity and C-ADP closure times is mediated via VWF:Ag levels, it is unlikely that any relationship between ADAMTS13 and C-EPI closure times would be of clinical relevance. This study was also performed when the evidence for statin therapy in TIA or ischaemic stroke was emerging,(33) so it will be of interest to see whether these data can be replicated in a larger cohort of patients on secondary preventative therapy with statins.
Conclusions
ADAMTS13 is a dynamic protease whose activity initially decreases and then returns towards baseline levels over time following TIA or stroke. VWF:Ag levels are increased in both the early and late phases after TIA or stroke onset, and can promote enhanced platelet adhesion or aggregation in response to stimulation with collagen-ADP at moderately high shear stress.
Further longitudinal studies in larger patient populations on other secondary preventive therapies are warranted to assess the profile of ADAMTS13 activity and VWF sub-fractions following TIA or ischaemic stroke, and its impact on platelet reactivity at different shear rates. This is especially important in view of the role that ADAMTS13 may have as a potential antithrombotic agent in CVD. (34) 
